Renal Pelvic Denervation Pilot Trial

StatusRecruiting
PhaseNot applicable
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial sites expanded: 5 → 9 locations
    • Start date changed from estimate of Dec 30, 2025 to Jan 30, 2026
    • Eligibility criteria expanded, about 36 words
    • Collaborators: 3 to 1
  2. Study sites: 2 to 5v3
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Jul 30, 2025 to Dec 30, 2025
    • Study sites: 0 to 2
    v2
  4. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The RPD Pilot trial will evaluate the safety and effectiveness of Verve Medical's RPDTM renal denervation system for hypertensive patients with uncontrolled blood pressure despite use of two medications at a therapeutic dose. The novelty of the RPDTM system relates to its placement via natural orifice into the renal pelvis (bilaterally) for delivery of radiofrequency energy to ablate the nerves that pass through the outer wall of the renal pelvis, a technique referred to as renal pelvic denervation (RPD).
Trial Details
NCT Number NCT07005050
Lead Sponsor Verve Medical, Inc
Collaborators: RQM+
Conditions
(from sponsor)		 Uncontrolled Hypertension
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov